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Background: Late familial hyperinsulinemic hypoglycemia is characterized by recurrent episodes of hypoglycemia
and an inappropriate insulinemic response. Treatment with octreotide (somatostatin analogue) reduces the
prevalence of clinical significant hypoglycemia and might be beneficial during pregnancy. To our knowledge this is
the first report of a woman with late familial hyperinsulinemic hypoglycemia experiencing pregnancies with and
without octreotide treatment.
Case presentation: A 35-year-old Caucasian woman known to suffer from late familial hyperinsulinemic hypoglycemia
due to a well-known mutation in the insulin receptor gene has been pregnant 6 times. The patient was treated with
injections of Sandostatin LAR® (octreotide) during the first four pregnancies. Her first pregnancy in 1999 was unknown
until approximately 25th gestational weeks with fatal intrauterine growth retardation. The following two pregnancies
were terminated on parental request after a chorion villus biopsy revealed the mutation causing late familial
hyperinsulinemic hypoglycemia. During the fourth pregnancy, in which the fetus also had the mutation, serial
ultrasound examinations showed a small fetus with appropriate growth. At birth the girl was small for gestational age.
She was admitted to the neonatal special care unit due to low blood glucose and intravenous glucose and early
feeding was initiated. One day old, her condition deteriorated with signs of an abdominal catastrophe indicating
necrotizing enterocolitis. After two laparotomies – both confirming necrotizing enterocolitis - the child died 8 days
after birth.
In the following two pregnancies Sandostatin LAR® was stopped before pregnancy and the patient was treated only
with diet restriction and intensive glucose monitoring. Both pregnancies ended successfully. One child carried the
mutation and was small for gestational age at birth while the other child did not carry the mutation and had normal
birth weight.
Conclusion: In a woman with late familial hyperinsulinemic hypoglycemia octreotide was given during the first four
pregnancies resulting in 2 cases of early termination of pregnancy on parental request and 2 cases of inappropriate
fetal growth and unviable outcome. The following two pregnancies treated with diet only had a successful outcome.
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Late familial hyperinsulinemic hypoglycemia (FHH) is
characterized by an inappropriate insulinemic response
[1,2]. Some of the causes can be gain-of-function muta-
tions in glucokinase or glutamate dehydrogenase, abnor-
mal pyruvate-induced insulin release, insulinomas or, as
in the present case, a missense mutation in the insulin
receptor gene.
This rare missense mutation in a tyrosine kinase do-
main in the insulin receptor causes severe postprandial
hypoglycemia, insulin resistance and decreased insulin
clearance. The mutation is autosomal-dominant and
with variable expression [1].
One way to treat recurrent episodes of severe hy-
poglycemia due to hyperinsulinemia is injections with
octreotide. This is a synthetic but more potent version
of the natural hormone somatostatin, which inhibits in-
sulin, glucagon and growth hormone with a prolonged
duration of action. Most of the limited experience with
administration of octreotide during pregnancy comes
from women being treated for acromegaly, and treat-
ment with octreotide during pregnancy in these cases is
generally considered safe [3].
Case presentation
A 35-year-old Caucasian woman known to suffer from
late FHH due to a well-known mutation [1] has been
pregnant 6 times with the result of 2 surviving children.
All the pregnancies are summarized in Table 1.
The disease’ first manifestation was recurrent episodes
of convulsions with loss of consciousness at the age of 12.
This was interpreted and treated as epilepsy until the age
of 21 (year 1999). At this time, measurements of capillary
blood glucose levels in the range of 1.1 – 1.5 mmol/L dur-
ing seizures led to measuring fasting plasma insulin (341
pmol/L) and S-insulin-to-C-peptide ratio (0.5). The pa-
tient began treatment with 30 mg intramuscular injections
of Sandostatin LAR® (octreotide) every four weeks and
new neuroglycopenic attacks were avoided. Three genera-
tions of family members showed similar episodes of severe
hypoglycemia and a genetic study of the family deter-










1999 Unknown 25 Unknown Yes
2008 Yes 10 + 3 Termination Yes
2008 Yes 10 + 6 Termination Yes
2009 Yes 37 + 6 2477 Yes
2010 Yes 36 + 0 2246 No
2012 No 37 + 2 2873 NoHer first pregnancy in 1999 was unacknowledged until
approximately 25th gestational week and showed fatal
intrauterine growth retardation. She had received San-
dostatin LAR® (30 mg every four weeks) throughout this
pregnancy.
In 2008 she was pregnant twice but each time a gen-
etic analysis from a chorion villus biopsy revealed the
mutation causing late FHH. The couple chose an in-
duced abortion in both cases.
In contrast, the pregnancy in 2009 was continued al-
though the fetus had the mutation. Throughout pregnancy
the patient was treated with 30 mg Sandostatin LAR®
every four weeks until gestational age (GA) 30 weeks.
Serial ultrasound examinations during pregnancy showed
a small fetus with appropriate growth velocity. At birth
the infant was small for gestational age (SGA) with a birth
weight of 2477 g, corresponding to −1.74 standard devia-
tions (SD) below the population mean [4]. Gestational dia-
betes was diagnosed at GA 27 weeks and her blood
glucose was well controlled on diet alone. One and a half
hours after an uncomplicated labor and delivery at GA
37 weeks +6 days, the newborn girl was admitted to the
neonatal special care unit due to low blood glucose and IV
glucose and early feeding was initiated. One and half days
old, her condition deteriorated with signs of an abdominal
catastrophe indicating necrotizing enterocolitis (NEC).
Laparotomy with resection of necrotic colon and a colos-
tomy was performed and treatment with IV antibiotics ini-
tiated. After the laparotomy the child briefly tolerated
feeding but few days later the colostomy became necrotic
and a second laparotomy showed intestinal necrosis from
ventricle to rectum. The child died 8.5 days old.
Based on these poor pregnancy outcomes and casuistic
reports on NEC in newborns treated with octreotide
[5,6] it was decided to stop Sandostatin LAR® before and
during following pregnancies. The patient was treated
with diet and daily self monitored plasma glucose with
intermittent continuous glucose monitoring with alarms
set for hypoglycemia (Guardian® Real-time Continuous
Glucose Monitoring System; Medtronic Minimed). The
diet consisted of at least 6–8 meals daily with carbohy-
drates of low-glycemic index.
In the following pregnancy in 2010 the female fetus had
the mutation and serial ultrasound measurements docu-
mented a small fetus with appropriate growth velocity.
The patient followed the described plan with diet and glu-
cose monitoring and no episodes of severe hypoglycemia
occurred. Birth weight at GA 36 weeks +0 days was
2246 g (SGA and corresponding to −1.56 SD). The final
pregnancy in 2012 the same treatment regime was
followed and resulted in a healthy girl without the mu-
tation. Birth weight at GA 37 weeks +0 days was 2873
g (−0.25 SD). Both infants had a spontaneous vaginal de-
livery and an uneventful neonatal period.
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We here present 6 pregnancies in the same woman car-
rying a rare mutation causing late familiar hyperinsuline-
mic hypoglycemia. Four pregnancies were continued
beyond the first trimester and 3 of these resulted in a
small for gestational age infant. Mutation status is not
known for the first of the 6 pregnancies, the 2nd to 5th
had the mutation, while the last child did not have the
mutation.
Theoretically the presence of a mutation causing late
FHH might cause inappropriate fetal growth. Glucose
passes the placenta and facilitates an increase in the insu-
lin level of the fetus. It is well known that insulin has the
effect of stimulating fetal growth [7]. A fetus with the mu-
tation in the insulin receptor could be immune to the dir-
ect effect of insulin as well as the indirect effect via
decreased uptake of metabolites such as glucose, lipids
and amino acids. This might cause impaired growth. In
contrast, a fetus without the mutation will have an appro-
priate insulin response that facilitates growth leading to an
appropriate birth weight. This is in accordance with the
studies from the group of Hattersley et al. looking into the
effect of fetal glucokinase mutations in offspring of women
with Maturity Onset Diabetes of the Young 2 [8].
Data on safety of octreotide application during preg-
nancy are very scarce and considering our report of two
fatal pregnancies during octreotide treatment one must
consider whether it is always safe to administer octreo-
tide during pregnancy.
There are no reports on NEC in infants being exposed
to octreotide during pregnancy, but Laje et al. reported
8 cases of NEC in infants with severe hypoglycemia sec-
ondary to hyperinsulinemia being treated with octreotide
[9]. On this background octreotide was not used in the
last 2 pregnancies. One of these 2 pregnancies where
octreotide was not used resulted in a small for gesta-
tional infant (+FHH mutation) while the other resulted
in an appropriate weight infant (−FHH mutation).
The combination of a mutation causing impaired fetal
growth with a drug that could affect fetal growth should
also be considered as a possible culprit. This could explain
why treatment with octreotide during pregnancy in
women with acromegaly is considered safe [10]. Also it
could explain why the pregnancy in 2010 with the muta-
tion present and no octreotide treatment ended successful;
although resulting in a small for gestational age infant.
In this case report we are not able to draw a final con-
clusion concerning causality.
However, we believe that our case supports the notion
that a mutation causing decreased fetal insulin function
might cause fetal impaired growth. Furthermore, the po-
tential role of octreotide in the development of NEC and
poor outcome in prenatally exposed infants should also
be considered and investigated. Until then, octreotidetreatment during pregnancy must be well indicated and
alternative treatments thought of before choosing this
course of treatment. Caution must be taken if the patient
in addition has a mutation that might induce impaired
fetal growth on its own.
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